Let’s talk about stacking. You don’t buy a single part when you need a whole system to perform. That’s the logic behind this blend. We’ve combined three of the most targeted, research-focused peptides for growth hormone study into one vial. This isn’t a random mix; it’s a strategic stack designed for synergistic action. Tesamorelin and CJC-1295 (Mod GRF) target the GHRH pathway, while Ipamorelin hits the GHSR (ghrelin receptor) pathway. It’s a two-pronged approach for a comprehensive research model. The result is a 12mg blend of precision-engineered compounds, manufactured and third-party tested right here in the USA.

What’s In The Blend & How It Works

You need to know what you’re working with. Here’s the breakdown:

• Tesamorelin (Synthetic GHRH Analog): A 44-amino acid peptide with specific structural modifications—an acetyl group at the N-terminus and a trans-3-hexenoic acid group at the C-terminus. These aren’t just for show; they’re designed to enhance stability and resist enzymatic degradation. In research, it’s been associated with significant increases in total GH output and IGF-1 levels.
• CJC-1295 (Mod GRF 1-29): This is the stabilized version. It’s tetrasubstituted (modifications at positions 2, 8, 15, 27) to drastically improve its half-life and binding affinity to the GHRH receptor. Think of it as the long-acting foundation of the GHRH signal in this stack.
• Ipamorelin (Selective GHSR Agonist): The key here is selectivity. Research indicates Ipamorelin targets the ghrelin receptor to prompt GH release without significant spillover into cortisol or ACTH pathways. It works through a different signaling cascade (PLC/IP3/DAG) than the GHRH analogs, making it a clean, complementary agent.

In simple terms, this blend engages two separate but complementary biological “switches” known to influence somatotrophs in the pituitary. It’s about coverage and potency.

Key Research Findings & Potential Applications

The data from individual compound studies informs the rationale for this combination. We’re summarizing peer-reviewed findings here for your research planning.

• GH & IGF-1 Output: In controlled settings, Tesamorelin exposure was linked to a ~69% increase in total GH and a ~122% rise in IGF-1. A CJC-1295 analog study reported a 70-107% increase in GH release over 12 hours and a ~28% increase in IGF-1. Ipamorelin has been shown to elevate GH secretion to levels significantly above placebo.
• Body Composition & Muscle Tissue: Research on a CJC-1295 analog noted increases in skeletal muscle mass. Tesamorelin studies using CT scans observed improvements in muscle tissue density and volume, alongside reductions in intramuscular fat in specific muscle groups. Ipamorelin research has pointed to its potential role in restoring nitrogen balance, a key factor in anabolism.
• Visceral Adiposity & Metabolic Factors: A primary area of Tesamorelin research has been visceral fat. Multiple studies have reported significant reductions in visceral adipose tissue (VAT), with one 52-week review noting a mean reduction of -17.5%, and others citing reductions up to -25%. Associated improvements in triglycerides and cholesterol have also been observed.
• Selectivity & Mechanism: Ipamorelin’s proposed selectivity for the GHSR is a noted feature, potentially allowing for targeted GH release without broad-spectrum endocrine disruption. The structural modifications in Tesamorelin and CJC-1295 are specifically intended to enhance receptor binding and delay degradation, aiming for a more pronounced and sustained signal.

Why Source This Blend From PeptideHub USA?

This isn’t a hobby. Your research demands reliability. Here’s what you get:

• Synergistic Formulation: This is a calculated stack, not a novelty. The combined action on GHRH and GHSR pathways is designed for a robust research model.
• Uncompromised Purity: Every batch is synthesized in a USA-based, ISO-certified laboratory and undergoes rigorous third-party mass spectrometry (HPLC) testing. The certificate of analysis is available. We verify the weight, purity, and sequence.
• Specification Transparency:
  
  Tesamorelin: Mol. Formula: C221H366N72O67S | Mol. Weight: 5136 g/mol
  
  CJC-1295 (Mod GRF 1-29): Mol. Formula: C152H252N44O42 | Mol. Weight: 3367.954 g/mol
  
  Ipamorelin: Mol. Formula: C38H49N9O5 | Mol. Weight: 711.868 g/mol
• Logistics You Can Count On: Order by 12 PM PST, it ships same day. Domestic shipping is fast and discreet. We are the source, not a middleman.

Important Researcher Notice

This product is for laboratory research use only. It is a chemical reagent not intended for human or animal consumption, diagnostic use, or